Form 8-K - Current report:
SEC Accession No. 0000318154-23-000011
Filing Date
2023-01-31
Accepted
2023-01-31 16:15:33
Documents
17
Period of Report
2023-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amgn-20230130.htm   iXBRL 8-K 63954
2 EX-10.1 exhibit101-amendmentno3tos.htm EX-10.1 27968
3 EX-99.1 amgn-20221231earningsrelea.htm EX-99.1 749904
4 EX-99.2 amgn-ex992_20221231xq4.htm EX-99.2 29146
9 GRAPHIC amgenlogoa14.jpg GRAPHIC 6206
  Complete submission text file 0000318154-23-000011.txt   1137189

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amgn-20230130.xsd EX-101.SCH 3079
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT amgn-20230130_def.xml EX-101.DEF 17303
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amgn-20230130_lab.xml EX-101.LAB 33541
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amgn-20230130_pre.xml EX-101.PRE 17597
11 EXTRACTED XBRL INSTANCE DOCUMENT amgn-20230130_htm.xml XML 14012
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 23572741
SIC: 2836 Biological Products, (No Diagnostic Substances)